RALFL20 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
RALFL20 antibody; At2g34825 antibody; F19I3 antibody; Protein RALF-like 20 antibody
Target Names
RALFL20
Uniprot No.

Target Background

Function
RALFL20 Antibody targets a cell signaling peptide that plays a significant role in regulating plant stress, growth, and development. This antibody mediates a rapid alkalinization of the extracellular space by triggering a transient increase in cytoplasmic Ca(2+) concentration. This, in turn, initiates calcium-dependent signaling events through a cell surface receptor and a subsequent activation of specific intracellular mitogen-activated protein kinases.
Database Links
Protein Families
Plant rapid alkalinization factor (RALF) family
Subcellular Location
Secreted.

Q&A

Here’s a structured FAQ for researchers investigating the RALFL20 Antibody, synthesized from peer-reviewed methodologies and experimental case studies. The questions are categorized into basic and advanced tiers, with methodological guidance reflecting best practices in antibody validation and application.

Advanced Research Questions

How can I engineer RALFL20 Antibody for enhanced antigen-sweeping functionality in vivo?

  • Engineering strategy:

    • Introduce pH-dependent binding mutations (e.g., histidine substitutions) to enable antigen release in endosomes .

    • Optimize FcRn affinity at neutral pH (e.g., YTE or v2 mutations) to prolong serum half-life .

    • Validate using pharmacokinetic modeling:

      ParameterConventional IgGEngineered IgG (v2 variant)
      Half-life (days)721
      Antigen Clearance Rate1x4x

What statistical approaches are recommended for reconciling contradictory neutralization data across labs?

  • Analysis framework:

    • Apply mixed-effects models to account for inter-lab variability in PRNT50 assays .

    • Standardize positive controls (e.g., WHO reference sera) across experiments .

    • Use coefficient of variation (CV) thresholds (<30%) for intra-assay reproducibility .

How does RALFL20 Antibody cross-reactivity with emerging variants impact therapeutic development?

  • Assessment workflow:

    • Screen against variant spike proteins (e.g., Omicron BA.2/BA.4.5 RBD) via ELISA .

    • Test neutralizing capacity using pseudovirus assays (IC50 ≤ 100 ng/mL = high potency) .

    • For non-neutralizing antibodies, evaluate Fc-mediated effector functions (ADCC, phagocytosis) .

Methodological Notes

  • Validation tiers:

    • Tier 1: Specificity confirmed in ≥2 applications (e.g., flow cytometry + IP) .

    • Tier 2: Functional validation (neutralization, epitope mapping) .

  • Critical pitfalls:

    • Avoid using Western blot as the sole validation method for conformation-sensitive antibodies .

    • Optimize storage buffers (e.g., 0.1% BSA + 0.02% sodium azide) to prevent aggregation .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.